Nanjing Drum Tower hospital

Running trials

• Recruiting

  Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure

  NCT07575672· Phase 3· Source

• Not yet recruiting

  Real-world Study of the Effectiveness and Tolerability of Outpatient Titration of OxyContin for the Moderate and Severe Pain in Cancer Patients

  NCT07869797· Source

• Recruiting

  Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)

  NCT07687459· Phase 3· Source

• Recruiting

  A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.

  NCT07653685· Phase 1/2· Source

• Not yet recruiting

  Sphere-9 PAF China Study

  NCT07789925· Source

• Not yet recruiting

  Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response

  NCT07797231· Phase 3· Source

• Not yet recruiting

  Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases

  NCT07745257· Phase 2· Source

• Recruiting

  A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity

  NCT07747857· Phase 1· Source

• Not yet recruiting

  A Prospective, Single-Arm, Multicenter Clinical Study of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma

  NCT07741617· Phase 2· Source

• Recruiting

  A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy

  NCT07468851· Phase 1/2· Source

• Recruiting

  A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours

  NCT07533708· Phase 1· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Source

• Recruiting

  A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects

  NCT07670884· Phase 3· Source

• Recruiting

  A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis

  NCT07406035· Phase 2· Source

• Not yet recruiting

  Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy

  NCT07627464· Phase 2· Source

• Recruiting

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· Phase 3· Source

• Recruiting

  A Multicenter, RAndomIzed, coNtrolled, umBrella Trial fOr Minimally Invasive Neurosurgery With AI-assisted Robotic guidanCe for Hemorrhagic Stroke

  NCT06459427· Source

• Recruiting

  A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions

  NCT07532538· Source

• Recruiting

  A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

  NCT07365995· Phase 3· Source

• Recruiting

  A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

  NCT07409181· Phase 2· Source

• Recruiting

  Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

  NCT07385703· Phase 3· Source

• Recruiting

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· Phase 3· Source

• Active, not recruiting

  A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic Agents

  NCT07472725· Phase 2· Source

• Recruiting

  A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

  NCT07355218· Phase 3· Source

• Recruiting

  A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  NCT07438496· Phase 3· Source

• Recruiting

  A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection

  NCT07367529· Phase 1/2· Source

• Recruiting

  A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· Phase 3· Source

• Recruiting

  Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke.

  NCT07396337· Phase 2· Source

• Recruiting

  Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  NCT07195695· Phase 3· Source

• Not yet recruiting

  Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations

  NCT07328919· Phase 3· Source

• Recruiting

  Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer

  NCT07298200· Phase 1· Source

• Recruiting

  A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT07225946· Phase 3· Source

• Recruiting

  Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

  NCT07185997· Phase 3· Source

• Recruiting

  A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus

  NCT07323173· Phase 1· Source

• Recruiting

  A Phase II Trial of LM103 in Advanced Melanoma

  NCT07310784· Phase 2· Source

• Recruiting

  A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors

  NCT07179679· Phase 1· Source

• Recruiting

  A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

  NCT07230106· Phase 2· Source

• Recruiting

  A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  NCT07276399· Phase 3· Source

• Recruiting

  A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

  NCT06937229· Phase 3· Source

• Active, not recruiting

  Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

  NCT07162883· Phase 3· Source

• Recruiting

  A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.

  NCT07641634· Phase 1/2· Source

• Not yet recruiting

  Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity

  NCT07135141· Source

• Recruiting

  Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery

  NCT07163650· Phase 4· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

  NCT06919965· Phase 3· Source

• Recruiting

  A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma.

  NCT07099430· Phase 1/2· Source

• Recruiting

  QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer

  NCT07110064· Phase 2· Source

• Recruiting

  A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07164443· Phase 3· Source

• Recruiting

  Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

  NCT07154706· Phase 3· Source

• Recruiting

  TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer

  NCT07047365· Phase 3· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer9 recruiting
• Lung cancer8 recruiting
• Gastric and esophageal cancer6 recruiting
• Multiple myeloma6 recruiting
• Lupus (SLE)5 recruiting
• Pancreatic cancer5 recruiting
• Bladder cancer4 recruiting
• Melanoma4 recruiting
• Metastatic breast cancer4 recruiting
• Obesity4 recruiting
• Alzheimer disease3 recruiting
• Colorectal cancer3 recruiting
• Fatty liver disease (MASLD/MASH)3 recruiting
• Head and neck cancer3 recruiting
• Hepatitis B3 recruiting
• High blood pressure3 recruiting
• Childhood cancers2 recruiting
• Heart failure2 recruiting
• Kidney cancer2 recruiting
• Liver and biliary tract cancer2 recruiting
• Stroke2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• Type 2 diabetes2 recruiting
• Acute myeloid leukemia1 recruiting
• Atrial fibrillation1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Endometrial cancer1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Ovarian cancer1 recruiting
• Primary biliary cholangitis1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Pulmonary arterial hypertension1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder

  NCT07252908· Phase 2· Source

• Recruiting

  A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer

  NCT07217301· Phase 3· Source

• Completed

  Efficacy and Safety of HRS9531 Tablet in Obese Subjects

  NCT06841445· Phase 2· Source

• Completed

  TGRX-678 Phase I Oral Pharmacokinetic Study

  NCT06697899· Phase 1· Source

• Completed

  Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

  NCT06670352· Phase 2· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Source

• Completed

  HTA of NIVATS Based on RWE

  NCT06574295· Source

• Completed

  DNA Methylation Biomarkers to Predict Survival After Surgery for Lung Adenocarcinoma

  NCT06477211· Source

• Completed

  RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

  NCT06173037· Phase 2· Source

• Completed

  A Clinical Study of JS005 in Patients With Ankylosing Spondylitis

  NCT06250062· Phase 2· Source

• Completed

  Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein

  NCT06142552· Phase 3· Source

• Completed

  Assessment of Gastric Emptying by SHR20004 in Healthy Subjects

  NCT06137469· Phase 1· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Source

• Terminated

  Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

  NCT06206278· Phase 2· Source

• Completed

  A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06049017· Phase 2· Source

• Completed

  A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

  NCT06068465· Phase 3· Source

• Completed

  Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery

  NCT07374445· Phase 4· Source

• Terminated

  A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis

  NCT05849727· Phase 2· Source

• Completed

  Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05938920· Phase 2· Source

• Completed

  A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects

  NCT05895565· Phase 1· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome

  NCT05673993· Phase 3· Source

• Completed

  Study to Assess PK, Safety and Tolerability in Healthy Subjects

  NCT06380699· Phase 1· Source

• Completed

  A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise

  NCT05628311· Phase 3· Source

• Completed

  A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients

  NCT05680155· Phase 3· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Source

• Completed

  Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate

  NCT05590793· Phase 3· Source

• Completed

  A Study of IBI362 in Participants With Obesity or Overweight

  NCT05607680· Phase 3· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Source

• Completed

  A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma

  NCT05420324· Phase 2· Source

• Completed

  To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

  NCT05253053· Phase 1/2· Source

• Completed

  Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes

  NCT07282054· Phase 3· Source

• Completed

  Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation

  NCT04942834· Source

• Completed

  EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

  NCT04509674· Phase 3· Source

• Completed

  Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC

  NCT04723004· Phase 3· Source

• Completed

  A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

  NCT04574284· Phase 2· Source

• Completed

  Efficacy and Influencing Factors of Secukinumab in Patients With Axial Spondyloarthritis

  NCT07130331· Source

• Completed

  A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma

  NCT04640545· Phase 1· Source

• Completed

  Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

  NCT04181788· Phase 1/2· Source

• Completed

  A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

  NCT04172675· Phase 2· Source

• Completed

  A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

  NCT04108208· Phase 4· Source

• Completed

  TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

  NCT03952091· Phase 3· Source

• Terminated

  A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

  NCT03758417· Phase 2· Source

• Completed

  A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

  NCT03234972· Phase 3· Source

• Completed

  A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

  NCT03217812· Phase 3· Source

• Terminated

  A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT03215030· Phase 1/2· Source

• Completed

  Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

  NCT02831959· Phase 3· Source